1. Association of statin pretreatment with presentation characteristics, infarct size and outcome in older patients with acute coronary syndrome: the Elderly ACS-2 trial
- Author
-
Anna Toso, Nuccia Morici, Mario Leoncini, Simona Villani, Luca A Ferri, Luigi Piatti, Daniele Grosseto, Irene Bossi, Paolo Sganzerla, Giovanni Tortorella, Michele Cacucci, Maurizio Ferrario, Stefano Tondi, Amelia Ravera, Francesco Bellandi, Claudio Cavallini, Roberto Antonicelli, Stefano De Servi, and Stefano Savonitto more...
- Subjects
Aging ,Incidence ,Humans ,ST Elevation Myocardial Infarction ,General Medicine ,Geriatrics and Gerontology ,Acute Coronary Syndrome ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Prognosis ,Aged - Abstract
Background prior statin treatment has been shown to have favourable effects on short- and long-term prognosis in patients with acute coronary syndrome (ACS). There are limited data in older patients. The aim of this study was to investigate the association of previous statin therapy and presentation characteristics, infarct size and clinical outcome in older patients, with or without atherosclerotic cardiovascular disease (ASCVD), included in the Elderly-ACS 2 trial. Methods data on statin use pre-admission were available for 1,192 of the 1,443 patients enrolled in the original trial. Of these, 531 (44.5%) were already taking statins. Patients were stratified based on established ASCVD and statin therapy. ACS was classified as non-ST elevation or ST elevation myocardial infarction (STEMI). Infarct size was measured by peak creatine kinase MB (CK-MB). All-cause death in-hospital and within 1 year were the major end points. Results there was a significantly lower frequency of STEMI in statin patients, in both ASCVD and No-ASCVD groups. Peak CK-MB levels were lower in statin users (10 versus 25 ng/ml, P Conclusions statin pretreatment was associated with more favourable ACS presentation and lower myocardial damage in older ACS patients both ASCVD and No-ASCVD. The incidence of all-cause death (in-hospital and within 1 year) was significantly lower in the statin treated ASCVD patients. more...
- Published
- 2021